

March 11, 2022

Resurgeonz LLC
Julie Lalonde
CEO
1550 Monte Carlo Court
Merritt Island, Florida 32952

Re: K213534

Trade/Device Name: PHantom Trilogy(TM) Regulation Number: 21 CFR 878.5400

Regulation Name: Low Level Laser System For Aesthetic Use

878.5650

Regulatory Class: Class II

Product Code: OLI

Dated: January 20, 2022 Received: January 24, 2022

#### Dear Julie Lalonde:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

K213534 - Julie Lalonde Page 2

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems">https://www.fda.gov/medical-device-problems</a>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</a>) and CDRH Learn (<a href="https://www.fda.gov/training-and-continuing-education/cdrh-learn">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</a>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Purva Pandya
Assistant Director
DHT4A: Division of General Surgery Devices
OHT4: Office of Surgical
and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

# DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

### **Indications for Use**

510(k) Number (if known)

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020

Expiration Date: 06/30/2020 See PRA Statement below.

K213534
Device Name
Resurgeonz pHantom Trilogy(TM)
Indications for Use (Describe)
Resurgeonz pHantom Trilogy(TM) is indicated for use as a non-surgical, non-invasive aesthetic treatment for the
temporary reduction of the circumference of waist, hips, thighs through the process of disrupting adipocyte cells, within the fat layer, for the release of fat and lipids from the targeted cells.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

## 510(k) SUMMARY

### 510(k) Summary of notification application K213534

Submitter Information			
Submitted By:	Resurgeonz		
Address	1550 Monte Carlo Court Merritt Island, Florida 32952		
Phone Number	321-222-5959		
Fax Number	N/A		
Establish Registration No.	622317		
Are You a Small Business?	Yes - SBD22819		
Name of Contact Person	Julie LaLonde		
Contact Person Address	1550 Monte Carlo Court Merritt Island, Florida 32952		
Contact Person Phone No.	407-233-6292		
Contact Person email	Admin@resurgeonz.com		
Date Prepared	November 29, 2020		
Name of Medical Device			
Trade or proprietary name	pHantom Trilogy <sup>™</sup>		
Common or usual name	Fat reducing Low Level Laser		
Classification name	Fat reducing Low Level Laser system for aesthetic use		
Classification panel	General & Plastic Surgery		
Regulation	21 CFR 880.5440		
Product Code(s)	ОЦ		
Device Classification	II		
Legally marketed device(s) to which equivalence is claimed	The Resurgeonz, pHantom Trilogy <sup>™</sup> has the following similarities to the predicate device, IR Technology's invisa-RED ELITE (K192275) and Laser LipoLTD, Strawberry and Strawberry and Cream (K130341).		

Reason for 510(k)	New device offering to the non-invasive aesthetic enhancement market.	
Device Description	The Resurgeonz pHantom Trilogy™ is a non-surgical, non-invasive, fat reducing low level laser system using a combination of Red and Infrared light spectrums to propagate laser frequencies of 660nm, 808nm and 980nm into a patient's dermal and adipose tissues for the reduction of the measured circumference of the patients waist, hips, and thighs. The device features an LCD touchscreen. Mode of operation is continuous. Allows individual patient session controls of: treatment time, energy, pulse and delay. Emergency safety cut off switch. Treatment applicators (multi diode paddles) connected to the device console can number 8,10, or 12. Paddles include built in air fan cooling. Combination of Coherent Frequencies of red and infrared: 26 diodes per big paddle, (13 red diodes at 660nm) and thirteen (13 infrared diodes) of the 13 infrared diodes, (6 diodes) are 808nm and (7 diodes) are 980nm. Two smaller paddles are available to swap out in place of two big paddles. The two smaller paddles only have 2 diodes each of red diodes at 660nm and are used for smaller hard to reach body areas. Power output or each diode is variable up to 72mW to per diode for all red and infrared diodes. The device does not have wireless and/or external wired communication. The device is powered by 120V, 60Hz. There is a side holder for paddles when not in use.	
Technological Characteristics	For comparison of technological characteristics with the predicates please see the table below.	
Performance Data	Resurgeonz pHantom TrilogyTM overall performance testing passed all specified test requirements of non-clinical (bench) tests conducted for determination of Substantial Equivalence (SE) results, and show of Substantial Equivalence (SE) with the predicate devices.	
Indication for Use	Resurgeonz pHantom Trilogy <sup>TM</sup> is indicated for use as a non- surgical, non-invasive aesthetic treatment for the temporary reduction of the circumference of waist, hips, thighs through the process of disrupting adipocyte cells, within the fat layer, for the release of fat and lipids from the targeted cells.	
Manufacturing Site	1550 Monte Carlo Court Merritt Island, FL 32952	
Environment for use	Healthcare provider office, Medi-Spas, and Clinics.	

Single patient use	No
Sterilization process	N/A - The Resurgeonz PHantom Trilogy <sup>™</sup> is supplied a non- sterile device. Cleaning instructions are provided in the User Manual.
Biocompatibility	Meets acceptance criteria per ISO 10993: Parts 1, 5, and 10 requirements
Conclusion on Substantial Equivalence	The Resurgeonz pHantom Trilogy <sup>™</sup> described and comparatively analyzed in this submission is determined to be Substantially Equivalent (SE) to the predicate device, for intended use, design, component and materials, operating principles, environment for use, performance, safety, effectiveness, product labeling and packaging, and is supported by the information provided in the 510(k) submission.
Conclusions drawn from non- clinical and clinical data	The Resurgeonz pHantom Trilogy™ meets the functional claims, and Intended Use as described in the product Labeling.
Statement of Safety and Efficacy	The safety and effectiveness are equivalent to the predicate device K192275 and predicate device K130341. The claim for Substantial Equivalence (SE) is supported by the information provided in the 510(k) submission.

Characteristic	Subject Device Resurgeonz, LLC PHantom Trilogy™	Predicate Device (K192275) IR Technology invisa-RED ELITE ™	Predicate Device Strawberry/Strawberry & Cream (K130341)
<b>Device Class</b>	li .	li .	II
Regulation Number	21 CFR 878.5400	21 CFR 878.5400	21 CFR 878.5400
Product Code(s)	оп	оп	OLI
Intended Use	Resurgeonz pHantom Trilogy™ is indicated for use as a non-surgical, non-invasive aesthetic treatment for the temporary reduction of the circumference of waist, hips, thighs through the process of disrupting adipocyte cells within the fat layer for the release of fat and lipids from the targeted cells.	The invisa-RED ™ is indicated for use as a non-invasive aesthetic treatment for the temporary reduction of the circumference of waist, hips, thighs through the process of photobiomodulation affecting adipocyte cells within the adipose layer for the release of lipids from these cells.	The Strawberry/Strawberry & Cream is indicated for use as a non-invasive aesthetic treatment for the temporary reduction in waist circumference by the disruption of adipocyte cells within the fat layer for the release of fat and lipids from these cells.
Technology	Laser lights in the visible red and infrared spectrums	Same	Laser lights in the visible red spectrum
Light Spectrum- Wavelength	Red light (Near Infrared) at 660nm and Infrared at 808nm and 980nm	Red light (Near Infrared) at 680nm and Infrared at 980nm	Red light (Near Infrared) 660 +/- 15nm
Light Waveform	Pulsed and Continuous	Same	Continuous

Laser Type	Diode Laser	Same	Same
Source Power	120VAC / 60Hz	120-240VAC / 50-60Hz	100-240V, 50-60Hz
Light Power Output	72mW each for Laser Diodes 660nm, 808nm and 980 nm	200mW per diode each for Laser Diodes both 680nm and 980nm	40 mW +/- 15% for each laser diode 660 nm
Number of Pads / Paddles	6, 8, 10 or 12 Big Paddles (optional) (size 130 x 66mm)	6, 8, 10, or 12 Big Paddles (optional) (size 130 x 66mm)	4,6,8 or 10 Big paddles (optional) (size similar)
Number of paddles/probes (size small)	2 (optional) with two 660nm diodes used to replace 2 big paddles	NA	2 with one 660nm diode each, included with big paddles
Number of diodes per big paddle	26 total, 13 red diodes and 13 infrared diodes	Same	6 red diodes per paddle
Number of diodes per small paddle	2 total, 2 red diodes only 660NM	NA	Similar 1 red diode per small paddle 660NM
Max number of Near Infrared diodes per system (red)	156	Same	62
Max number of Infrared diodes per system	156	Same	NA
Energy Delivery	Machine mounted paddles	Same	NA
Display	TFT Color Touchscreen LCD	Same	same
Console/Housing	ABS Plastic	Same	similar
Safety Features	Emergency stop button/key switch	same	same
Dust and Liquid ingression	Rated IPXO	Not rated	Not rated

Paddle Cooling	Forced air cooled system	Same	NA
Target Population	18 years old and over	Same	Same
Environment for use	Healthcare provider office, MediSpas,and Clinics	Same	Same
Time of treatment	10-20 minutes	15-20 minutes	10-20 minutes
Target body areas	Waist, hips, thighs	Same	waist
Biocompatibility	Meets acceptance criteria per ISO 10993: Parts 1, 5, and 10 requirements	Same	similar
Sterility	Non sterile	Same	Same
Environmental Conditions for Use	Operating Temperature: 15.5°C ~ 26.6°C Operating Relative Humidity: ≤80%	Same	Same
Labeling	Product warnings and User Manual	Similar	Similar
Big Pad Dimension	130mm x 66mm	130mm x 66mm	152.4mm x 50.8mm
Small Pad Dimension	66mm x 45mm	N/A	57.15mm x 50.8mm
Device Dimension	Approximately 44" x 18" x 14"	Approximately 38.6" x 18.5" x 19.68" (98cm x 47cm x 50cm)	12" x 12" x 13"
Device Weight	Approximately 66.14 lbs	108 lbs	13 lbs